PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data ...
Guardant's third-quarter revenue soared by 39% year over year to $265.2 million. The gains were broad based. Revenue in the healthcare company's biopharma division jumped 18% to $54.7 million. Sales ...
Diagnostics company Guardant Health (NASDAQ:GH) reported Q1 CY2026 results , with sales up 48.3% year on year to $301.7 million. The company’s full-year revenue guidance of $1.31 billion at the ...
View source version on businesswire.com: https://www.businesswire.com/news/home/20230223005809/en/ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results